PHILLYRIN AND ITS DERIVATIVES FOR SUPPRESSION OF THE 3CLPRO PROTEIN AND FIGHTING THE COVID-19 VIRUS Russian patent published in 2023 - IPC A61K31/34 A61K31/7048 A61P31/14 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the use of phillyrin and/or its derivatives, and/or phillyrin/philligenin compositions, as well as methods for using the above active ingredients. The use of phillyrin and phillyrin derivatives KD-2-GLU and KD-2-SO₃H is proposed, these compounds are represented by the following formulas:

in the preparation of an agent for inhibiting 3CLpro protein of the COVID-19 virus. Also the methods for inhibiting the 3CLpro protein of the COVID-19 virus are provided, comprising the step of reacting the 3CLpro protein of the COVID-19 virus with phillyrin or any of the above-mentioned phillyrin derivatives KD-2-GLU and KD-2-SO₃H. It is proposed to use a composition of phillyrin/philligenin with a weight ratio of phillyrin to philligenin 2~ 98:2~98 as the sole pharmaceutically active ingredient in the preparation of a medicinal product against the COVID-19 virus or a medicinal product for the treatment of a disease caused by the COVID-19 virus, as well as methods for combating the COVID-19 virus or treating a disease caused by the COVID-19 virus, comprising the step of administering to a patient in need an effective amount of the aforementioned phillyrin/philligenin composition or a medicament containing such phillyrin/philligenin composition as the sole pharmaceutically active ingredient.

EFFECT: phillyrin and the above derivatives of phillyrin have a specific effect inhibiting 3CLpro protein of the COVID-19 virus, the phillyrin/philligenin composition significantly inhibits the COVID-19 virus and overexpression of inflammatory mediators.

11 cl, 8 tbl, 4 ex, 8 dwg